Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accounts Payables (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Accounts Payables for 13 consecutive years, with $67.2 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 772.28% year-over-year to $67.2 million; the TTM value through Mar 2026 reached $67.2 million, up 772.28%, while the annual FY2025 figure was $53.3 million, 442.66% up from the prior year.
  • Accounts Payables hit $67.2 million in Q1 2026 for Viking Therapeutics, up from $53.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $67.2 million in Q1 2026 and bottomed at $254000.0 in Q3 2024.
  • Average Accounts Payables over 5 years is $12.2 million, with a median of $5.7 million recorded in 2023.
  • Year-over-year, Accounts Payables tumbled 95.55% in 2024 and then soared 1637.4% in 2025.
  • Viking Therapeutics' Accounts Payables stood at $8.5 million in 2022, then dropped by 11.92% to $7.5 million in 2023, then skyrocketed by 30.63% to $9.8 million in 2024, then skyrocketed by 442.66% to $53.3 million in 2025, then grew by 26.16% to $67.2 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $67.2 million, $53.3 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.